Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

Executive Summary

BD and BioMedomics will soon begin distributing a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.

You may also be interested in...



COVID-19: Nanomix Wins BARDA Funding For Mobile Point-Of-Care Assay

The US government’s Biomedical Advanced Research and Development Authority has awarded Nanomix up to $570,000 to develop a SARS-CoV-2 test for its portable, rapid Nanomix eLab analyzer.

FDA Open To Home COVID-19 Testing With Caveats, OIVD’s Stenzel Says

The US FDA is open to the idea of home-testing for the COVID-19 virus, but only after making sure the test is completely safe and effective, and available only through a physician’s oversight, said Tim Stenzel, director of the agency’s Office of In Vitro Diagnostics and Radiological Health.

Belgium Bans COVID-19 Antibody Self-Tests But UK Goes Ahead

While the UK is moving forward quickly to provide COVID-19 antibody self-testing, the Belgian government considers the tests not sufficiently accurate to be used in the pandemic.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel